Stanley D. Chamberlain

1.8k total citations
35 papers, 1.0k citations indexed

About

Stanley D. Chamberlain is a scholar working on Molecular Biology, Epidemiology and Organic Chemistry. According to data from OpenAlex, Stanley D. Chamberlain has authored 35 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Epidemiology and 12 papers in Organic Chemistry. Recurrent topics in Stanley D. Chamberlain's work include Cytomegalovirus and herpesvirus research (7 papers), HIV/AIDS drug development and treatment (6 papers) and Biochemical and Molecular Research (5 papers). Stanley D. Chamberlain is often cited by papers focused on Cytomegalovirus and herpesvirus research (7 papers), HIV/AIDS drug development and treatment (6 papers) and Biochemical and Molecular Research (5 papers). Stanley D. Chamberlain collaborates with scholars based in United States, United Kingdom and Belgium. Stanley D. Chamberlain's co-authors include Vasu Nair, George W. Koszalka, John C. Drach, Leroy B. Townsend, Gregory A. Turner, Jean‐Luc Girardet, Michael T. Migawa, John Walker, Mui Cheung and Kirk L. Stevens and has published in prestigious journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Stanley D. Chamberlain

34 papers receiving 981 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stanley D. Chamberlain United States	19	476	429	185	177	158	35	1.0k
Linda L. Wotring United States	22	684 1.4×	632 1.5×	223 1.2×	233 1.3×	131 0.8×	69	1.5k
Michael F. Gardner United States	19	174 0.4×	615 1.4×	145 0.8×	96 0.5×	114 0.7×	37	1.3k
Yuichi Yoshimura Japan	24	1.1k 2.4×	937 2.2×	194 1.0×	424 2.4×	96 0.6×	127	1.8k
Daniel Vitt Germany	20	168 0.4×	435 1.0×	205 1.1×	84 0.5×	137 0.9×	45	906
Esther Martinborough United States	10	230 0.5×	416 1.0×	231 1.2×	146 0.8×	63 0.4×	16	1.1k
Jiancun Zhang China	25	1.5k 3.0×	631 1.5×	118 0.6×	65 0.4×	185 1.2×	68	2.3k
Amartya Basu United States	23	439 0.9×	457 1.1×	104 0.6×	172 1.0×	165 1.0×	40	1.2k
Daniel P. Getman United States	20	451 0.9×	784 1.8×	108 0.6×	225 1.3×	149 0.9×	31	1.4k
Mark L. Behnke United States	15	605 1.3×	749 1.7×	107 0.6×	208 1.2×	248 1.6×	18	1.4k
Landon R. Whitby United States	19	452 0.9×	914 2.1×	85 0.5×	111 0.6×	191 1.2×	24	1.4k

Countries citing papers authored by Stanley D. Chamberlain

Since Specialization

Citations

This map shows the geographic impact of Stanley D. Chamberlain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley D. Chamberlain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley D. Chamberlain more than expected).

Fields of papers citing papers by Stanley D. Chamberlain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley D. Chamberlain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley D. Chamberlain. The network helps show where Stanley D. Chamberlain may publish in the future.

Co-authorship network of co-authors of Stanley D. Chamberlain

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley D. Chamberlain. A scholar is included among the top collaborators of Stanley D. Chamberlain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley D. Chamberlain. Stanley D. Chamberlain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

McGuigan, Christopher, Marco Derudas, Nadège Hamon, et al.. (2013). Design, synthesis and biological evaluation of phosphorodiamidate prodrugs of antiviral and anticancer nucleosides. European Journal of Medicinal Chemistry. 70. 326–340. 25 indexed citations

McGuigan, Christopher, Karolina Madela, Arnaud Gilles, et al.. (2011). Dual pro-drugs of 2′-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Bioorganic & Medicinal Chemistry Letters. 21(19). 6007–6012. 14 indexed citations

McGuigan, Christopher, Karolina Madela, Arnaud Gilles, et al.. (2010). Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorganic & Medicinal Chemistry Letters. 20(16). 4850–4854. 73 indexed citations

Sabbatini, Peter, Susan Korenchuk, Jason L. Rowand, et al.. (2009). GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics. 8(10). 2811–2820. 86 indexed citations

Rabindran, Sridhar K., Peter Sabbatini, Susan Korenchuk, et al.. (2009). Abstract #1740: Characterization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Cancer Research. 69. 1740–1740. 2 indexed citations

Patnaik, Samarjit, Kirk L. Stevens, Felix Deanda, et al.. (2009). Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 19(11). 3136–3140. 20 indexed citations

Emmitte, Kyle A., C. Webb Andrews, Ramesh Bambal, et al.. (2009). Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorganic & Medicinal Chemistry Letters. 19(6). 1694–1697. 54 indexed citations

Conway, James G., Sarva M. Tadepalli, Peiyuan Lin, et al.. (2008). Effects of the cFMS Kinase Inhibitor 5-(3-Methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in Normal and Arthritic Rats. Journal of Pharmacology and Experimental Therapeutics. 326(1). 41–50. 48 indexed citations

Cheung, Mui, Philip A. Harris, Stanley D. Chamberlain, et al.. (2008). The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 18(20). 5428–5430. 36 indexed citations

10.

Chamberlain, Stanley D., Anikó M. Redman, Samarjit Patnaik, et al.. (2008). Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: Elimination of an acid-mediated decomposition pathway. Bioorganic & Medicinal Chemistry Letters. 19(2). 373–377. 15 indexed citations

11.

Chamberlain, Stanley D., Joseph W. Wilson, Felix Deanda, et al.. (2008). Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: Potent inhibitors of the IGF-1R receptor tyrosine kinase. Bioorganic & Medicinal Chemistry Letters. 19(2). 469–473. 27 indexed citations

12.

Smalley, Terrence L., Stanley D. Chamberlain, Wendy Y. Mills, et al.. (2007). Synthesis of novel anilinoquinolines as c-fms inhibitors. Bioorganic & Medicinal Chemistry Letters. 17(22). 6257–6260. 11 indexed citations

13.

Chamberlain, Stanley D., et al.. (2006). Multiple vaccine and pyridostigmine interactions: Effects on EEG and sleep in the common marmoset. Pharmacology Biochemistry and Behavior. 84(2). 282–293. 3 indexed citations

14.

Chan, Joseph H., Stanley D. Chamberlain, Karen K. Biron, et al.. (2000). Synthesis and Evaluation of a Series of 2′-Deoxy Analogues of The Antiviral Agent 5,6-Dichloro-2-Isopropylamino-1-(β-L-Ribofuranosyl)-1H-Benzimidazole (1263W94). Nucleosides Nucleotides & Nucleic Acids. 19(1-2). 101–123. 7 indexed citations

15.

Chulay, Jeffrey D., Karen K. Biron, Mark Underwood, et al.. (1999). Development of Novel Benzimidazole Riboside Compounds for Treatment of Cytomegalovirus Disease. Advances in experimental medicine and biology. 458. 129–134. 39 indexed citations

16.

Townsend, Leroy B., Kristjan S. Gudmundsson, Susan M. Daluge, et al.. (1999). Studies Designed to Increase the Stability and Antiviral Activity (HCMV) of the Active Benzimidazole Nucleoside, TCRB. Nucleosides and Nucleotides. 18(4-5). 509–519. 27 indexed citations

17.

Chamberlain, Stanley D., Karen K. Biron, Ronna E. Dornsife, et al.. (1994). An Enantiospecific Synthesis of the Human Cytomegalovirus Antiviral Agent [(R)-3-((2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-4- hydroxybutyl]phosphonic Acid. Journal of Medicinal Chemistry. 37(9). 1371–1377. 21 indexed citations

18.

Chamberlain, Stanley D., Allan R. Moorman, Thimysta C. Burnette, P de Miranda, & Thomas A. Krenitsky. (1994). Novel Carbohydrate Conjugates as Potential Prodrugs of Acyclovir. Antiviral chemistry & chemotherapy. 5(2). 64–73. 4 indexed citations

19.

Moorman, Allan R., et al.. (1992). Di- and triester prodrugs of the varicella-zoster antiviral agent 6-methoxypurine arabinoside. Journal of Medicinal Chemistry. 35(1). 56–63. 12 indexed citations

20.

Nair, Vasu & Stanley D. Chamberlain. (1985). Novel photoinduced carbon-carbon bond formation in purines. Journal of the American Chemical Society. 107(7). 2183–2185. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact